文献速递流行病学与生物统计真实世界研究与卫生经济

HIV治疗资格扩大与入组后及时启动抗逆转录病毒治疗:22国项目数据的元回归分析

HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries.
PubMed 文献 · PLoS Med · 2018-03-23

该研究基于22国171个IeDEA站点284,740例初治成人HIV患者,分析2007至2015年国家政策扩大ART资格后6个月内及时启动ART的变化。随机效应元回归显示,扩大至CD4≤350和CD4≤500后,及时启动率分别提高4.3和15.9个百分点,新符合条件者增幅最大,年轻患者(16-24岁)在CD4≤500扩大后增幅达21.5个百分点。

要点

  • 扩大ART资格至CD4≤350或≤500可显著提高入组后6个月内及时启动ART的比例。
  • 新符合治疗条件者获益最大,原符合条件者变化较小或仅小幅增加。
  • CD4≤500扩大后,16-24岁年轻患者及时启动率增幅最大。

核心结论

  • ART资格扩大可改善全球及时启动ART的比例,尤其对年轻成人效果显著。

研究设计与样本

  • 基于22国171个IeDEA站点284,740例初治成人HIV患者的项目数据,采用随机效应元回归分析。
  • 分析2007至2015年国家政策扩大ART资格前后6个月内及时启动ART的变化。

主要发现

  • 扩大至CD4≤350后,及时启动率粗合并变化为4.3个百分点(95%CI 2.6-6.1),基线中位及时启动率为53%。
  • 扩大至CD4≤500后,及时启动率粗合并变化为15.9个百分点(95%CI 14.3-17.4),基线中位及时启动率为57%。
  • 新符合条件者及时启动率增幅最大:扩大至CD4≤350为18.2个百分点,扩大至CD4≤500为47.4个百分点。
  • 原符合条件者变化较小:CD4≤350为-0.6个百分点(95%CI -2.0-0.7),CD4≤500为4.9个百分点(95%CI 3.3-6.5)。
  • 扩大至CD4≤500后,16-24岁患者及时启动率增幅为21.5个百分点(95%CI 18.9-24.2)。

临床怎么用

  • 扩大ART治疗资格可能提高新入组患者及时启动ART的比例。
  • 对年轻成人患者,扩大治疗资格可能带来更明显的及时启动改善。

局限性

  • 缺乏反事实对照,难以排除结局的时间趋势影响,因各国普遍暴露于指南变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of antiretroviral treatment (ART) eligibility expansions on patient outcomes, including rates of timely ART initiation among those enrolling in care, has not been assessed on a large scale. In addition, it is not known whether ART eligibility expansions may lead to "crowding out" of sicker patients. METHODS AND FINDINGS: We examined changes in timely ART initiation (within 6 months) at the original site of HIV care enrollment after ART eligibility expansions among 284,740 adult ART-naïve patients at 171 International Epidemiology Databases to Evaluate AIDS (IeDEA) network sites in 22 countries where national policies expanding ART eligibility were introduced between 2007 and 2015. Half of the sites included in this analysis were from Southern Africa, one-third were from East Africa, and the remainder were from the Asia-Pacific, Central Africa, North America, and South and Central America regions. The median age of patients enrolling in care at contributing sites was 33.5 years, and the median percentage of female patients at these clinics was 62.5%. We assessed the 6-month cumulative incidence of timely ART initiation (CI-ART) before and after major expansions of ART eligibility (i.e., expansion to treat persons with CD4 ≤ 350 cells/μL [145 sites in 22 countries] and CD4 ≤ 500 cells/μL [152 sites in 15 countries]). Random effects metaregression models were used to estimate absolute changes in CI-ART at each site before and after guideline expansion. The crude pooled estimate of change in CI-ART was 4.3 percentage points (95% confidence interval [CI] 2.6 to 6.1) after ART eligibility expansion to CD4 ≤ 350, from a baseline median CI-ART of 53%; and 15.9 percentage points (pp) (95% CI 14.3 to 17.4) after ART eligibility expansion to CD4 ≤ 500, from a baseline median CI-ART of 57%. The largest increases in CI-ART were observed among those newly eligible for treatment (18.2 pp after expansion to CD4 ≤ 350 and 47.4 pp after expansion to CD4 ≤ 500), with no change or small increases among those eligible under prior guidelines (CD4 ≤ 350: -0.6 pp, 95% CI -2.0 to 0.7 pp; CD4 ≤ 500: 4.9 pp, 95% CI 3.3 to 6.5 pp). For ART eligibility expansion to CD4 ≤ 500, changes in CI-ART were largest among younger patients (16-24 years: 21.5 pp, 95% CI 18.9 to 24.2 pp). Key limitations include the lack of a counterfactual and difficulty accounting for secular outcome trends, due to universal exposure to guideline changes in each country. CONCLUSIONS: These findings underscore the potential of ART eligibility expansion to improve the timeliness of ART initiation globally, particularly for young adults.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Tymejczyk O, Brazier E, Yiannoutsos C, et al. HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Med. 2018. PMID: 29570723. doi:10.1371/journal.pmed.1002534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。